In an exclusive conversation with Business Today, Camilla Sylvest, Executive Vice President, Commercial Strategy & Corporate ...

Novo Nordisk is intervening in the lawsuit filed by a drug compounders trade group against the FDA over the agency’s decision ...

Novo Nordisk warns of potential price hikes and shortages amid global tariff threats, impacting drug prices and supply chains ...

Danish obesity drug giant looking at whether its semaglutide drug can reduce cravings associated with addiction ...

Novo Nordisk’s GLP-1 drug Semaglutide, sold under brand names Ozempic and Wegovy, has been hailed as a miracle drug for ...

The European makers of Ozempic for diabetes and Cetaphil for dry skin said they would feel an impact from President Donald ...

"We are currently engaging with market participants," a spokesperson for South Africa's Competition Commission told Reuters, declining to provide details. USAID cuts put tuberculosis response in peril ...

As a federal court in Texas hears a case pitting the FDA versus compounders who want to continue to manufacture cheaper ...

The FDA recently announced that Novo Nordisk’s semaglutide GLP-1 medication (Ozempic and Wegovy) is no longer in short supply ...

U.S. taxpayers spent billions developing Ozempic-type diabetes and weight-loss drugs — now those drugs’ markups could ...

Novo Nordisk (NVO) plans to study how its GLP-1 drugs marketed as Wegovy and Ozempic for obesity and diabetes can help tackle ...